Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 14, 2023
-
Nov 17, 2023
-
Oct 13, 2023
-
Sep 12, 2023First-in-class ALTUVIIIO offers clinically proven highly effective bleed protection with once-weekly dosing for children with hemophilia A
-
Aug 24, 2023The recommendation helps to ensure all infants have the opportunity to be protected from RSV disease ahead of the next winter virus season
-
May 5, 202317 abstracts showcase new data for Dupixent, itepekimab and anti-IL-13/TSLP NANOBODY® molecule in COPD and asthma
-
Apr 27, 2023
-
Mar 23, 2023First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo
-
Mar 18, 2023More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks
-
Dec 21, 2022Dupixent 300 mg weekly showed significant histological disease remission and improvement in symptoms of the disease compared to placebo
-
Dec 2, 2022Four Sarclisa® (isatuximab-irfc) oral presentations and 11 posters featuring cutting-edge investigational and marketed therapies to be presented
-
Sep 28, 2022Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials
-
Sep 19, 2022
-
Jul 21, 2022
- Clinical trials will be conducted at Centers of Excellence at four historically Black medical schools
- The Beacon of Hope program aims to strengthen clinical trial capabilities, improve the quality and inclusivity of clinical trials and help rebuild trust in the healthcare system within Black communities
- Initiative is part of Sanofi's broader commitment to increase clinical trial diversity throughout the entire ecosystem – from study design and eligibility criteria to site selection, recruitment materials, and engagement with local communities
-
Jul 14, 2022First and only investigational Phase 3 trial to show positive results in these young children; results follow recent approval of Dupixent in people with eosinophilic esophagitis aged 12 years and older who weigh at least 40 kilograms
-
Jul 10, 2022- A median annualized bleeding rate (ABR) of 0.0 was reported in the overall study population during fitusiran prophylaxis (80 mg monthly)
-
Jul 10, 2022- Investigational once-weekly efanesoctocog alfa prophylaxis met the primary efficacy endpoint providing clinically meaningful bleed protection for people with severe hemophilia A
-
Jun 29, 2022Through the Insulins Valyou Savings Program, uninsured people living with diabetes will pay fixed $35 for a 30-day supply of Sanofi insulins
-
Jun 22, 2022Results of nationally representative survey come as the ACIP evaluates data to provide guidance for flu vaccines in this vulnerable population
-
Jun 7, 2022Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood